Yükleniyor... / Loading...
This study evaluates the costs and clinical outcomes of a pharmacogenetic testing program, which uses a patient's genetic information to guide medication choices. Adults aged 18 and older who were newly prescribed one of 27 index medications and who received care at the participating health systems were able to take part. It was conducted as a study with no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: Patients will be eligible for inclusion if they are prescribed one of the 27 index medications for the first time, defined as there being no recorded prescription in the Eskenazi, Indiana University Health or Indiana Patient Care (INPC) system over the past year. The inclusion criteria that will be adhered to will be: 1. Able and willing consent to participation in the trial; 2. Adults aged 18 and over; 3. Receiving care at Eskenazi Health or Indiana University Health Systems for 1 year or more; 4. Prescribed an index medication. 5. No documented prescription of the index medication for the past year. 6. The study limit of enrollment (500) for that medication has not been reached 7. A single tube of whole blood can be obtained, and 8. Able to follow study procedures. - Exclusion Criteria: No subject will be excluded from the study on the basis of ethnicity or race. We will include all minorities. Patients will be excluded if they: 1. Cannot or do not consent to participate; 2. are unable to provide 5cc of whole blood, or it cannot be obtained; 3. if they are an employee or student under the supervision of any of the investigators.